Clinical trials
Metastatic Liver Cancer clinical trials
Below are recruiting metastatic liver cancer clinical trials, each written for real people, not researchers. We’re tracking 817 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06728852RecruitingPhase 2
Vorolanib for advanced lung cancer after other treatments
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–70 - NCT04646759RecruitingPhase 3
Fulvestrant or capecitabine plus pyrotinib for metastatic breast cancer
This Phase 3 trial tests adding pyrotinib to standard hormone-based treatments (fulvestrant or capecitabine) to slow or control metastatic breast cancer. It’s for tumors that are hormone-receptor positive and HER2 positive, where standard options have been used before.
Guangzhou, GuangdongAges 18–80 - NCT06155396RecruitingPhase 2
Targeted drug combo for advanced cervical cancer
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Bengbu, AnhuiAges 18 years+ - NCT06184698RecruitingPhase 2
Liposomal irinotecan, chemotherapy, and bevacizumab for advanced colorectal cancer
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
Shijiazhuang, HebeiAges 18–75 - NCT04516681RecruitingPhase 3
Ascorbic acid plus immunotherapy for spread colorectal cancer
This trial tests whether intravenous vitamin C (ascorbic acid) combined with an immune treatment (adebrelimab) can slow or shrink metastatic colorectal cancer that can’t be removed with surgery. It focuses on tumors that strongly show a specific marker called GLUT3, and aims to see if the combination works better than standard approaches.
Shanhai, Shanghai MunicipalityAges 18–75 - NCT06411600RecruitingPhase 2
Combination therapy for BRAF-mutated colorectal cancer
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
BarcelonaAges 18 years+ - NCT06572813RecruitingPhase 1/Phase 2
Combination therapy for advanced pancreatic cancer
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
Hangzhou, ZhejiangAges 18–75 - NCT07392346RecruitingPhase 2
Fruquintinib combo for advanced gastric cancer after immunotherapy
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03579836RecruitingPhase 1/Phase 2
Test BEY1107 plus gemcitabine for pancreatic cancer
This early study tests whether BEY1107 given alone or with gemcitabine can be used safely and may help shrink pancreatic cancer tumors. It mainly looks at safety, side effects, and signs of effectiveness in people with pancreatic ductal cancer.
SeoulAges 20–80 - NCT07192614RecruitingPhase 1/Phase 2
Study of AZD6621 for men with advanced prostate cancer
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
Orlando, FloridaAges 18 years+ - NCT07136428RecruitingPhase 1/Phase 2
Asciminib for HER2+ breast cancer that has spread to the brain
This trial tests the drug asciminib for people with HER2-positive breast cancer that has spread to the brain and is growing. It may be an option if you have already tried standard treatments like T-DXd and tucatinib.
Durham, North CarolinaAges 18 years+ - NCT06515470RecruitingPhase 1
Testing BTX-9341 for advanced breast cancer
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
Rochester, MinnesotaAges 18 years+ - NCT06755515Enrolling by invitationPhase 2/Phase 3
Rulonilimab + Chemo for Advanced Cervical Cancer
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
Linyi, ShandongAges 18 years+ - NCT06591650RecruitingPhase 2
Combination therapy for advanced gallbladder cancer
This trial is testing a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) for people with gallbladder cancer that has spread or cannot be removed by surgery. The goal is to see if this drug combination helps shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06253611RecruitingPhase 2
Probiotic plus immunotherapy and chemo for stomach cancer
This trial tests a new combination for advanced stomach cancer: an experimental probiotic (EXL01) plus standard immunotherapy (nivolumab) and chemotherapy (FOLFOX). It is for people whose tumors have a high PD-L1 marker and who have not received prior treatment for advanced disease.
AngersAges 18 years+ - NCT05748834RecruitingPhase 2
Tucatinib plus Doxil for HER2-positive metastatic breast cancer
This Phase 2 study tests tucatinib (a HER2-targeted pill) plus Doxil (a chemotherapy medicine) to slow or shrink HER2-positive metastatic breast cancer that has been treated before. It may help by targeting HER2 cancer cells more effectively than past treatments alone.
Columbia, MarylandAges 18 years+ - NCT05093231RecruitingPhase 2
Pembrolizumab plus olaparib for stage 4 pancreatic cancer
This trial tests whether combining pembrolizumab (an immunotherapy) with olaparib (a DNA-repair drug) can work better for people with metastatic (stage 4) pancreatic cancer. It targets tumors with certain lab marker results and aims to improve control of cancer growth.
MelbourneAges 18 years+ - NCT02422641RecruitingPhase 2
High-dose methotrexate for breast cancer in the brain lining
This Phase 2 trial tests whether giving high-dose methotrexate into the bloodstream can help treat breast cancer that has spread to the thin lining covering the brain and spinal cord. It may help reduce cancer in the leptomeningeal (brain-lining) area and control symptoms.
Baltimore, MarylandAges 18 years+ - NCT06249750RecruitingPhase 2
Heat shock therapy for castration-resistant prostate cancer
This trial tests a near-infrared whole-body heat shock technique to treat prostate cancer that no longer responds to hormone therapy. It aims to see if this heat-based approach can help control the cancer.
Hangzhou, ZhejiangAges 18–90 - NCT06851299RecruitingPhase 2
Trop2-ADC alone or with immunotherapy for advanced triple-negative breast cancer
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–70 - NCT07159048Recruiting
Heat therapy for liver tumors
This trial tests a heat-based treatment for liver cancer tumors that uses multiple methods to destroy cancer cells. It may help people with liver tumors that haven't spread and who are healthy enough for treatment.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06473961RecruitingPhase 1
GC101 cell therapy for advanced non-small cell lung cancer
This trial tests an experimental cell therapy (GC101) for people with advanced non-small cell lung cancer. It uses your own tumor-fighting immune cells, called TILs, grown in a lab and given back to you. The goal is to see if it can shrink tumors or slow the disease.
ShanghaiAges 18–70 - NCT04443088RecruitingPhase 1
Study drug INV-1120 with or without pembrolizumab for advanced cancers
This Phase 1 trial studies INV-1120 alone and with pembrolizumab (an immune therapy) in adults with advanced solid tumors that have stopped responding to standard treatment or have no standard option. The goal is to see how the treatments work, what dose is safest, and what side effects may occur.
Lafayette, IndianaAges 18 years+ - NCT03259867RecruitingPhase 2
TACE plus immune therapy for liver or stomach cancer
This trial tests a combination treatment using a targeted liver procedure plus an immune “checkpoint” medicine to slow cancer growth. It may help people with advanced liver cancer (HCC) or metastatic stomach cancer when standard treatments have not worked.
Orange, CaliforniaAges 18–80
Hear when a new Metastatic Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic liver cancer?
- Yes. Clin2 currently lists 817 recruiting metastatic liver cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic liver cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic liver cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.